The Canadian journal of cardiology · 1995
Evaluation of myocardial infarction therapy at a Canadian tertiary referral hospital.
Клиническое исследованиеСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Leung M, Brown G, Webb J
Аннотация
OBJECTIVE: To evaluate the appropriateness of acute and postmyocardial infarction (MI) treatment.
DESIGN: A retrospective chart review.
SETTING: Tertiary care teaching hospital.
PATIENTS: All patients admitted with a potential MI or who experienced an MI during their hospital stay from November 18, 1991 to September 20, 1992.
RESULTS: For acute treatment, thrombolytics, acetylsalicylic acid (ASA) and intravenous beta-blockers were used in 82%, 96% and 39% of eligible patients with a median time delay of 1.4, 4.4 and 1.8 h, respectively. For post-MI treatment, ASA, oral beta-blockers, warfarin and angiotensin-converting enzyme inhibitors were used in 93%, 68%, 50% and 71% of eligible patients, respectively.
CONCLUSIONS: ASA use was considered acceptable while the other therapies were underused. The time delays in the initiation of therapies were also considered longer than desirable. Ongoing audit may aid in improving the quality of care in future patients with an MI.
DESIGN: A retrospective chart review.
SETTING: Tertiary care teaching hospital.
PATIENTS: All patients admitted with a potential MI or who experienced an MI during their hospital stay from November 18, 1991 to September 20, 1992.
RESULTS: For acute treatment, thrombolytics, acetylsalicylic acid (ASA) and intravenous beta-blockers were used in 82%, 96% and 39% of eligible patients with a median time delay of 1.4, 4.4 and 1.8 h, respectively. For post-MI treatment, ASA, oral beta-blockers, warfarin and angiotensin-converting enzyme inhibitors were used in 93%, 68%, 50% and 71% of eligible patients, respectively.
CONCLUSIONS: ASA use was considered acceptable while the other therapies were underused. The time delays in the initiation of therapies were also considered longer than desirable. Ongoing audit may aid in improving the quality of care in future patients with an MI.